Navegar por autor "Valladares Ayerbes, Manuel"

A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues

2011- Rodriguez Rigueiro, Teresa; Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Aparicio Gallego, Guadalupe; [et al.]

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

2011- Valladares Ayerbes, Manuel

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colo

2013- Valladares Ayerbes, Manuel

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

2011- Valladares Ayerbes, Manuel

Biological influence of Hakai in cancer: a 10-year review

2012- Valladares Ayerbes, Manuel; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Figueroa Conde-Valvís, Angélica; Figueroa Conde-Valvís, Angélica [et al.]

Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

2014- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; [et al.]

Circulating MicroRNAs: Molecular microsensors in gastrointestinal cancer

2012- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Figueroa Conde-Valvís, Angélica; [et al.]

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

2015- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; [et al.]

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

2012- Valladares Ayerbes, Manuel; Reboredo Lopez, Margarita; Medina Villaamil, Vanessa; Iglesias Díaz, Pilar; Lorenzo Patiño, María José; [et al.]

Circulating miR-337-3p as a novel biomarker for prostate cancer

2013- Valladares Ayerbes, Manuel; Antón Aparicio, Luis Miguel; Gómez Veiga, Francisco; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; [et al.]

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study

2012- Valladares Ayerbes, Manuel

Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach

2015- Valladares Ayerbes, Manuel; Blanco Calvo, Moisés; Figueroa Conde-Valvís, Angélica; Concha Lopez, Angel

Combination of KIR2DS4 and Fc gamma RII alpha polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

2019- Borrero-Palacios, A.; Cebrian, A.; del Pulgar, M. T. G.; Garcia-Carbonero, R.; Garcia-Alfonso, P.; [et al.]

Combination of KIR2DS4 and FcgammaRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

2019- Borrero-Palacios, A; Cebrian, A; Gomez Del Pulgar, M T; Garcia-Carbonero, R; Garcia-Alfonso, P; [et al.]

Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort

2015- Valladares Ayerbes, Manuel

Current controversies in the management of metastatic colorectal cancer

2015- Valladares Ayerbes, Manuel

Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)

2015- Valladares Ayerbes, Manuel

Effect of a microtubule-targeting drug on cell-cell contacts in bladder epithelial tumour cells

2014- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Figueroa Conde-Valvís, Angélica [et al.]

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer

2012- Valladares Ayerbes, Manuel; Blanco Calvo, Moisés; Reboredo Lopez, Margarita; Lorenzo Patiño, María José; Iglesias Díaz, Pilar; [et al.]

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study

2012- Valladares Ayerbes, Manuel

Repositorio digital RUNA

Navegar por autor "Valladares Ayerbes, Manuel"

A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues ﻿

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens ﻿

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colo ﻿

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143) ﻿

Biological influence of Hakai in cancer: a 10-year review ﻿

Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer ﻿

Circulating MicroRNAs: Molecular microsensors in gastrointestinal cancer ﻿

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer ﻿

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer ﻿

Circulating miR-337-3p as a novel biomarker for prostate cancer ﻿

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study ﻿

Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach ﻿

Combination of KIR2DS4 and Fc gamma RII alpha polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer ﻿

Combination of KIR2DS4 and FcgammaRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer ﻿

Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort ﻿

Current controversies in the management of metastatic colorectal cancer ﻿

Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD) ﻿

Effect of a microtubule-targeting drug on cell-cell contacts in bladder epithelial tumour cells ﻿

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer ﻿

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study ﻿

A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colo

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

Biological influence of Hakai in cancer: a 10-year review

Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

Circulating MicroRNAs: Molecular microsensors in gastrointestinal cancer

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

Circulating miR-337-3p as a novel biomarker for prostate cancer

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study

Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach

Combination of KIR2DS4 and Fc gamma RII alpha polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Combination of KIR2DS4 and FcgammaRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort

Current controversies in the management of metastatic colorectal cancer

Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)

Effect of a microtubule-targeting drug on cell-cell contacts in bladder epithelial tumour cells

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study